Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the pharmacokinetic profile of Revlimid® in
patients presenting with Multiple Myeloma and impaired renal function, the safety of
Revlimid® in the enrolled patients population.
and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM
and impaired renal function at completion of 3 cycles of treatment.